The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 01, 2021

Filed:

Jun. 23, 2017
Applicants:

Institut Pasteur, Paris, FR;

Centre National DE LA Recherche Scientifique, Paris, FR;

Ministère Des Armées—direction Centrale Du Service DE Santé Des Armées, Paris, FR;

Inventors:

Frederic Tangy, Les Lilas, FR;

Anastassia Komarova, Arcueil, FR;

Marie Mura, Avrainville, FR;

Chantal Combredet, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/165 (2006.01); A61K 39/12 (2006.01); A61K 39/295 (2006.01); A61K 39/015 (2006.01); A61K 39/39 (2006.01); A61P 33/00 (2006.01); A61P 31/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 39/015 (2013.01); A61K 39/39 (2013.01); A61P 31/00 (2018.01); A61P 33/00 (2018.01); A61K 2039/51 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/545 (2013.01); A61K 2039/555 (2013.01); A61K 2039/55588 (2013.01); A61K 2039/70 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16234 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18443 (2013.01); C12N 2760/18444 (2013.01); C12N 2770/36134 (2013.01); Y02A 50/30 (2018.01);
Abstract

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5' copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.


Find Patent Forward Citations

Loading…